Agenus is an immuno-oncology company driven by innovation and speed. Our goal is to treat cancers with novel combinations utilizing our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines and adjuvants. In addition to a broad portfolio, we have an accomplished team of scientists, novel technology platforms and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. With our remarkable combination of science and people, we believe that we are uniquely positioned to bring curative treatments to cancer patients.
For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.
Follow @Agenus_Bio on Twitter to stay up to date! https://twitter.com/Agenus_Bio
For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.
Follow @Agenus_Bio on Twitter to stay up to date! https://twitter.com/Agenus_Bio
Location: United States
Employees: 201-500
Phone: +1 781-674-4200
Total raised: $200M
Founded date: 1994
Investors 3
| Date | Name | Website |
| 14.05.2021 | EW Healthc... | ewhealthca... |
| - | Advent Lif... | adventls.c... |
| - | UVA Licens... | lvg.virgin... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.07.2021 | - | $200M | - |
Mentions in press and media 17
| Date | Title | Description |
| 10.03.2026 | Agenus: $20 Million Triggered Under Zydus Life Sciences Collaboration To Support BOT And BAL Manufacturing | Agenus announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus Life Sciences to support manufacturing activities for its lead immuno-oncology programs botens... |
| 03.06.2025 | Zydus buys Agenus' biologics plants in US for $125 mn, licenses cancer therapy | - |
| 03.06.2025 | Agenus Receives Investment from Zynext Ventures | Agenus, a Lexington, MA-based immuno-oncology company developing new therapeutics for high-unmet need cancers, received an investment from Zynext Ventures. The amount of the deal was not disclosed. Led by CEO Dr. Garo Armen, Agenus develops... |
| 13.09.2024 | GSK shingles vaccine now available in Malaysia | A vaccine for the prevention of shingles in adults aged 50 and over and those aged 18 and over at increased risk KUALA LUMPUR, Malaysia, Sept. 13, 2024 /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch ... |
| 12.09.2024 | AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit | NEW YORK, Sept. 12, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July... |
| 16.05.2024 | HSA approves GSK's Arexvy, the world's first respiratory syncytial virus (RSV) vaccine for older adults [1] | Arexvy has been approved by the Health Sciences Authority (HSA) of Singapore for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and... |
| 13.03.2023 | Agenus Cancels Conference Call to Discuss the Company's Minority Cash Holdings at SVB in Light of Government's SVB Deposit Access Announcement | LEXINGTON, Mass., March 12, 2023 (GLOBE NEWSWIRE) -- Agenus AGEN, a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced that it has cancelled its ... |
| 07.03.2022 | Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™ | Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™ Mon, Mar 07, 2022 13:00 CET Report this content The parties have entered into a collaboration agreement to develop Targovax´s TG mu... |
| 06.07.2021 | Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777 | LEXINGTON, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activa... |
| 28.03.2019 | Bristol-Myers Squibb, Concerto HealthAI team up on real-world data, artificial intelligence | Physicians often use the term “real world” to refer to the use of interventions outside the confines of a clinical trial. Real-world data means evidence gathered through routine patient care from sources like electronic health records, medi... |
Show more